Clinical Trials Directory

T3 for Fibromyalgia: a Pilot Double-blind Non-randomized Clinical Trial

Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia. Determine the feasibility and promise of an appropriately powered future prospective randomized controlled study of using T3 (the active form of thyroid hormone) for the treatment of fibromyalgia. We specifically aim to assess the feasibility, cost, obstacles and promise of conducting a prospective controlled study in the future.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : T3
  • drug : Placebo

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 50 Years

Inclusion Criteria

1. Age 18-50 2. Meet american college of rheumatology criteria for fibromyalgia 3. at baseline report an average pain of 4 or more on a brief Pain Inventory. 4. can climb 2 flights of stairs without shortness of breath.

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Rebecca McCue
6507240522
Not Recruiting

Footer Links: